NCT07172269View on ClinicalTrials.gov

Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

May 26, 2025

Study Completion Date

May 26, 2025

Conditions
Diabete MellitusType 2 DiabetesObesity Type 2 Diabetes MellitusDyslipidemia in Patients With Diabetes MellitusInsulin Resistance
Interventions
DRUG

Sitagliptin + Metformin

Oral tablets, 50/1000 mg, taken twice daily after meals for 12 weeks

DIETARY_SUPPLEMENT

mangosteen supplement

Capsules, 500 mg, taken twice daily after meals for 12 weeks

BEHAVIORAL

Lifestyle Management

Diabetes education, diet counseling, and exercise guidance provided throughout the 12-week study period.

Trial Locations (1)

Unknown

National Diabetes Center for Treatment and Research, Baghdad

All Listed Sponsors
lead

Mais Qais Hbeeb

OTHER

NCT07172269 - Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter